Mechanisms of resistance to imatinib (STI571) and prospects for combination with conventional chemotherapeutic agents

Drug Resistance Updates

Volumn 4, Issue 1, 2001, Pages 16-21

  Krystal, Geoffrey W ^a  

^a VIRGINIA COMMONWEALTH UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; ANTINEOPLASTIC AGENT; CYTARABINE; DAUNORUBICIN; HYDROXYUREA; IMATINIB; PROTEIN TYROSINE KINASE; UNCLASSIFIED DRUG;

CANCER RESISTANCE; CELL LINE; CHRONIC MYELOID LEUKEMIA; CLINICAL TRIAL; DRUG ACTIVITY; DRUG EFFICACY; DRUG MECHANISM; DRUG POTENCY; DRUG POTENTIATION; DRUG STRUCTURE; ENZYME ACTIVATION; ENZYME SPECIFICITY; HUMAN; NONHUMAN; PRIORITY JOURNAL; SHORT SURVEY;

EID: 0035056924     PISSN: 13687646     EISSN: None     Source Type: Journal    
DOI: 10.1054/drup.2000.0176     Document Type: Article

References (36)

1. Lessons learned from the development of an Abl tyrosine kinase inhibitor for chronic myelogenous leukemia
2. Tyrosine kinase activity and transformation potency of bcr-abl oncogene products
3. Induction of chronic myelogenous leukemia in mice by the P210bcr/abl gene of the Philadelphia chromosome
4. Induction of a chronic myelogenous leukemia-like syndrome in mice with v-abl and BCR/ABL
5. Selective inhibition of the platelet-derived growth factor signal transduction pathway by a protein-tyrosine kinase inhibitor of the 2-phenylaminopyrimidine class
6. Inhibition of the Abl protein-tyrosine kinase in vitro and in vivo by a 2-phenylaminopyrimidine derivative
7. Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells
8. CGP 57148, a tyrosine kinase inhibitor, inhibits the growth of cells expressing BCR-ABL, TEL-ABL, and TEL-PDGFR fusion proteins
9. The tyrosine kinase inhibitor CGP57148B selectively inhibits the growth of BCR-ABL-positive cells
10. In vivo eradication of human BCR/ABL-positive leukemia cells with an ABL kinase inhibitor
11. Clinical efficacy and safety of an Abl specific tyrosine kinase inhibitor as targeted therapy for chronic myelogenous leukemia
12. Intracranial inhibition of platelet-derived growth factor-mediated glioblastoma growth by an orally active kinase inhibitor of the 2-phenylaminopyrimidine class
13. Autocrine growth of small cell lung cancer mediated by coexpression of c-kit and stem cell factor
14. Induction of apoptosis and inhibition of small cell lung cancer growth by the quinoxaline tyrphostins
15. The selective tyrosine kinase inhibitor STI571 inhibits small cell lung cancer growth
16. Inhibition of c-kit receptor tyrosine kinase activity by STI571, a selective tyrosine kinase inhibitor
17. Abl protein-tyrosine kinase inhibitor STI571 inhibits in vitro signal transduction mediated by c-Kit and platelet-derived growth factor receptors
18. Identification of a point mutation in the catalytic domain of the proto-oncogene c-kit in peripheral blood mononuclear cells of patients with systemic mastocytosis with an associated hematologic disorder
19. Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors
20. Activating c-kit mutations in human germ cell tumors
21. Tyrosine kinase inhibition; an approach to drug development
22. Structures of the tyrosine kinase domain of fibroblast growth factor receptor in complex with inhibitors
23. Structural mechanism for STI571 inhibition of Abelson tyrosine kinase
24. Activity of an Abl specific tyrosine kinase inhibitor in patients with Bcr-Abl positive acute leukemias, including chronic myelogenous leukemia in blast crisis
25. Selection and characterization of BCR-ABL positive cell lines with differential sensitivity to the tyrosine kinase inhibitor STI571: Diverse mechanisms of resistance
26. Mechanisms of resistance to the ABL tyrosine kinase inhibitor STI571 in BCR/ABL-transformed hematopoietic cell lines
27. Induction of resistance to the Abelson inhibitor STI571 in human leukemic cells through gene amplification
28. + leukemic cells to the Abl inhibitor STI571
29. Dragons 'round the fleece again: STI571 versus α1 glycoprotein
30. Epidermal growth factor receptor family and chemosensitization
31. Antitumor effect and potentiation of cytotoxic drugs activity in human cancer cells by ZD-1839 (Iressa), an epidermal growth factor receptor-selective tyrosine kinase inhibitor
32. Inhibition of epidermal growth factor receptor-associated tyrosine phosphorytation in human carcinomas with CP-358,774: Dynamics of receptor inhibition in situ and antitumor effects in athymic mice
33. CGP57148B (STI571) induces differentiation and apoptosis and sensitizes Bcr-Abl-positive human leukemia cells to apoptosis due to antileukemic drugs
34. Efficacy of STI571, an Abl tyrosine kinase inhibitor, in conjunction with other antileukemic agents against Bcr-Abl-positive cells
35. The susceptibility of Philadelphia chromosome positive cells to FAS-mediated apoptosis is not linked to the tyrosine kinase activity of BCR-ABL
36. Selective inhibition of cell proliferation and BCR-ABL phosphorylation in acute lymphoblastic leukemia cells expressing Mr 190,000 BCR-ABL protein by a tyrosine kinase inhibitor (CGP-57148)